Rosângela de Albuquerque Ribeiro
Research Subjects
Rosângela de Albuquerque Ribeiro has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Gonçalves de Oliveira
Fundação Hemominas, Belo Horizonte, Brazil
3 shared publications - Claudia Santos Lorenzato
Centro de Hematologia e Hemoterapia do Paraná (HEMEPAR) Curitiba Brazil
3 shared publications - Maíse Moreira Dias
Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
3 shared publications - Ricardo Mesquita Camelo
Universidade Federal de Minas Gerais
3 shared publications - Suely Meireles Rezende
Department of Internal Medicine, Faculty of Medicine Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil
3 shared publications - Vivian Karla Brognoli Franco
Centro de Hematologia e Hemoterapia de Santa Catarina (HEMOSC), Florianópolis, Brazil
3 shared publications
Latest Publications
- 1 May 2025
- Published by Elsevier in Thrombosis Research
- Vol. 250, 109336
Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study
- 1 May 2025
- Published by Elsevier in Thrombosis Research
- Vol. 250, 109336
Cost of immune tolerance induction according to its outcome in people with hemophilia A and inhibitors: results from the Co$tIT study
- Open Access
- 17 November 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S152-S157
Epidemiology of immune thrombocytopenia: study of adult patients at a referral hematology service in Northeastern Brazil
- 17 November 2023
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 46 (Suppl 5) , S152-S157
Open AccessEpidemiology of immune thrombocytopenia: study of adult patients at a referral hematology service in Northeastern Brazil
- 24 February 2023
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (1) , 74-80
Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction
Hemophilia A (HA) is a hereditary X-linked bleeding disorder, characterized by the deficiency of the clotting factor VIII (FVIII) due to mutations in its coding gene (F8).1 Breakthrough bleedings, ...
- 24 February 2023
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (1) , 74-80
Changing recombinant factor VIII to plasma-derived factor VIII during immune tolerance induction
Hemophilia A (HA) is a hereditary X-linked bleeding disorder, characterized by the deficiency of the clotting factor VIII (FVIII) due to mutations in its coding gene (F8).1 Breakthrough bleedings, ...
- 14 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (11) , 2526-2537
Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study
- 14 September 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (11) , 2526-2537
Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study
- Open Access
- 1 December 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (12) , 1116-1122
Factor VIII prophylactic therapy reduces neurological complications in patients with Hemophilia A
Background: Bleeding in hemophiliacs can cause complications in the central and peripheral nervous system (CNS and PNS). The incidence of intracranial hemorrhage has reduced after the introduction of prophylactic treatment with factor VIII or IX, but the benefits of this therapy have not yet been evaluated on PNS complications. Objective: The aim of this study was to determine the prevalence of neurological complications in hemophiliacs and verify the effect of prophylactic therapy in these patients, including PNS disorders. Methods: We retrospectively evaluated the prevalence of CNS and PNS disorders caused by bleeding in hemophiliacs seen at the Hemocentro Regional Norte, Ceará, Brazil, from 1992 to 2018, and we compared the incidence in different periods (before and after the introduction of prophylactic treatment in 2011). Results: Of 75 hemophilia A patients evaluated (4.61/100.000 population), 13.3% (n=10) had either CNS (n=5) or PNS (n=5) disorders secondary to bleeding. Patients submitted to factor VIII replacement prophylactic therapy were less likely to have CNS events: from 1992 to 2011, 5 of 63 patients had CNS disease, while from 2011 to 2018, there were no new cases (p=0.0181). From 2011 to 2018, 5 PNS events occurred in patients without prophylactic therapy, whereas none occurred in those covered by prophylactic therapy (5/20 versus 0/29, p=0.0081). Conclusions: The prevalence of neurological complications in hemophiliacs in our cohort is similar to other studies. Similar to CNS, prophylactic therapy also reduces the risk of PNS complications. This is the first report in the literature showing this benefit.
- 1 December 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (12) , 1116-1122
Open AccessFactor VIII prophylactic therapy reduces neurological complications in patients with Hemophilia A
Background: Bleeding in hemophiliacs can cause complications in the central and peripheral nervous system (CNS and PNS). The incidence of intracranial hemorrhage has reduced after the introduction of prophylactic treatment with factor VIII or IX, but the benefits of this therapy have not yet been evaluated on PNS complications. Objective: The aim of this study was to determine the prevalence of neurological complications in hemophiliacs and verify the effect of prophylactic therapy in these patients, including PNS disorders. Methods: We retrospectively evaluated the prevalence of CNS and PNS disorders caused by bleeding in hemophiliacs seen at the Hemocentro Regional Norte, Ceará, Brazil, from 1992 to 2018, and we compared the incidence in different periods (before and after the introduction of prophylactic treatment in 2011). Results: Of 75 hemophilia A patients evaluated (4.61/100.000 population), 13.3% (n=10) had either CNS (n=5) or PNS (n=5) disorders secondary to bleeding. Patients submitted to factor VIII replacement prophylactic therapy were less likely to have CNS events: from 1992 to 2011, 5 of 63 patients had CNS disease, while from 2011 to 2018, there were no new cases (p=0.0181). From 2011 to 2018, 5 PNS events occurred in patients without prophylactic therapy, whereas none occurred in those covered by prophylactic therapy (5/20 versus 0/29, p=0.0081). Conclusions: The prevalence of neurological complications in hemophiliacs in our cohort is similar to other studies. Similar to CNS, prophylactic therapy also reduces the risk of PNS complications. This is the first report in the literature showing this benefit.
- Open Access
- 1 May 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (5) , 571-572
Hemostasis profile in COVID-19 infection
According to some current studies, the infection by COVID-19 (SARS- CoV-2) appears to be associated with the involvement of hemostasis in the Chinese population, developing to Acute Respiratory Distress Syndrome (ARDS). The context reported here focuses on cases with ARDS, which has been implicated with the presence of an endothelial lesion, production of pro-coagulating factors, and generation of fibrin degradation product (D-dimer), compatible with disseminated intravascular coagulation (DIC).1 The increase in the concentration of D-dimer 3-4 times above the normal levels was associated with the outcome of death and there are reports of thromboembolic phenomena, and factors of worse prognosis, such as advanced age, low immunity, neutrophilia, and organ and coagulation dysfunction.2 Patients who develop a more severe response to the disease may evolve to dyspnea and hypoxemia within one week from the onset of the disease and may progress rapidly to ARDS or target organ failure. Among other possibilities, coagulation, in the cases that have been reported in the literature, consists of prolonged prothrombin time (PT) and partial activated thromboplastin time (APTT) in 2.1% and 9.7%, respectively, of the patients who had ARDS. Epidemiological data report that changes in coagulation, in COVID-19 infections, associated with ARDS and the systemic inflammatory process, may react releasing a large amount of pro-inflammatory cytokines - tumor necrosis factor, interleukin (IL) -1, IL -6 and IL-8 - although the pathogenesis of human COVID19 has not yet been fully clarified. Studies reinforce the hypothesis that the great increase in the production of cytokines is associated with a deficient immune system and are the two main triggers of events that culminate in the serious evolution of the infection.1 , 2 In this context, it is important to develop preventive measures, as well as laboratory tests and early prognostic markers of patients who will present the severe form, so that a therapeutic approach is performed in the initial phase in patients affected by COVID-19. This way, it will be possible to avoid the evolution to death in this group of patients, since the course of the disease can be quick, progressing to ARDS within one week from the onset of the disease, in addition to target organ failure.2 Comparing the laboratory tests of patients with and without ARDS, it was noticed that the group with ARDS had significant changes in index values, i.e., liver injury, renal dysfunction, related to inflammation and coagulation function. Also, the lymphocyte count and CD8 T cells were significantly decreased. In addition to this worrying matter, patients who developed ARDS did not respond well to treatments with antiretrovirals.2 Given these facts, it is of utmost importance to evaluate the benefit laboratory tests and prognostic markers, on hospital admission, could bring to favor those patients who will evolve to the severe form, aiming at early preventive and therapeutic measures, to avoid evolution to unfavorable outcomes. Among the important tests so far, we can mention blood count, PT, APTT, and D-dimer, which have all been mentioned and whose correlations were observed in the literature as prognostic markers, as follows: severe lymphopenia, neutrophilia, and thrombocytopenia at the complete blood count; extended PT and increased D-dimer are associated with cases of severe evolution.3 - 5 However, the guidance to patients who were already using oral anticoagulant medications, before contracting COVID-19, is to continue with the treatment; however, greater laboratory and clinical monitoring of these patients is necessary, as recommended by Chinese studies that note that altered PT, even at mild levels, is also a factor of poor prognosis and reinforce that, in this scenario, the patient/control relationship should be used instead of the INR.
- 1 May 2020
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 66 (5) , 571-572
Open AccessHemostasis profile in COVID-19 infection
According to some current studies, the infection by COVID-19 (SARS- CoV-2) appears to be associated with the involvement of hemostasis in the Chinese population, developing to Acute Respiratory Distress Syndrome (ARDS). The context reported here focuses on cases with ARDS, which has been implicated with the presence of an endothelial lesion, production of pro-coagulating factors, and generation of fibrin degradation product (D-dimer), compatible with disseminated intravascular coagulation (DIC).1 The increase in the concentration of D-dimer 3-4 times above the normal levels was associated with the outcome of death and there are reports of thromboembolic phenomena, and factors of worse prognosis, such as advanced age, low immunity, neutrophilia, and organ and coagulation dysfunction.2 Patients who develop a more severe response to the disease may evolve to dyspnea and hypoxemia within one week from the onset of the disease and may progress rapidly to ARDS or target organ failure. Among other possibilities, coagulation, in the cases that have been reported in the literature, consists of prolonged prothrombin time (PT) and partial activated thromboplastin time (APTT) in 2.1% and 9.7%, respectively, of the patients who had ARDS. Epidemiological data report that changes in coagulation, in COVID-19 infections, associated with ARDS and the systemic inflammatory process, may react releasing a large amount of pro-inflammatory cytokines - tumor necrosis factor, interleukin (IL) -1, IL -6 and IL-8 - although the pathogenesis of human COVID19 has not yet been fully clarified. Studies reinforce the hypothesis that the great increase in the production of cytokines is associated with a deficient immune system and are the two main triggers of events that culminate in the serious evolution of the infection.1 , 2 In this context, it is important to develop preventive measures, as well as laboratory tests and early prognostic markers of patients who will present the severe form, so that a therapeutic approach is performed in the initial phase in patients affected by COVID-19. This way, it will be possible to avoid the evolution to death in this group of patients, since the course of the disease can be quick, progressing to ARDS within one week from the onset of the disease, in addition to target organ failure.2 Comparing the laboratory tests of patients with and without ARDS, it was noticed that the group with ARDS had significant changes in index values, i.e., liver injury, renal dysfunction, related to inflammation and coagulation function. Also, the lymphocyte count and CD8 T cells were significantly decreased. In addition to this worrying matter, patients who developed ARDS did not respond well to treatments with antiretrovirals.2 Given these facts, it is of utmost importance to evaluate the benefit laboratory tests and prognostic markers, on hospital admission, could bring to favor those patients who will evolve to the severe form, aiming at early preventive and therapeutic measures, to avoid evolution to unfavorable outcomes. Among the important tests so far, we can mention blood count, PT, APTT, and D-dimer, which have all been mentioned and whose correlations were observed in the literature as prognostic markers, as follows: severe lymphopenia, neutrophilia, and thrombocytopenia at the complete blood count; extended PT and increased D-dimer are associated with cases of severe evolution.3 - 5 However, the guidance to patients who were already using oral anticoagulant medications, before contracting COVID-19, is to continue with the treatment; however, greater laboratory and clinical monitoring of these patients is necessary, as recommended by Chinese studies that note that altered PT, even at mild levels, is also a factor of poor prognosis and reinforce that, in this scenario, the patient/control relationship should be used instead of the INR.
- Open Access
- 1 July 2019
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 41 (3) , 253-261
Proposal of treatment algorithm for immune thromocytopenia in adult patients of a hematology service at a referral center in Northeastern Brazil
- 1 July 2019
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 41 (3) , 253-261
Open AccessProposal of treatment algorithm for immune thromocytopenia in adult patients of a hematology service at a referral center in Northeastern Brazil